Merck reported lower sales, just below Wall Street estimates, hurt by competition from cheaper generic medicines.» Read More
Amgen Inc. fell $1.42 or 1.1 percent, to $122.54. Biogen Idec rose$. 44 or. 1 percent, to $332.49. Celgene Corp. fell $6.59 or 4.2 percent, to $149.41.
March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.
Amgen Inc. rose$. 40 or. 3 percent, to $124.36. Biogen Idec rose $6.88 or 2.1 percent, to $338.93. Celgene Corp. fell $4.33 or 2.8 percent, to $151.67.
Amgen Inc. fell$. 50 or. 4 percent, to $123.46. Biogen Idec rose $1.81 or. 5 percent, to $333.86. Celgene Corp. fell $7.53 or 4.8 percent, to $148.47.
Amgen Inc. fell $2.02 or 1.6 percent, to $123.96. Biogen Idec fell $7.50 or 2.2 percent, to $332.05. Celgene Corp. fell $1.92 or 1.2 percent, to $156.00.
March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.
March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.
WASHINGTON, March 4- In a case eagerly watched by publicly traded companies regularly sued by investors, the U.S. Supreme Court will on Wednesday consider overruling a 26- year-old precedent that made it easier for plaintiffs to negotiate large class action settlements.
Feb 5- Merck& Co Inc's quarterly profit and sales just missed expectations as its medicines faced competition from cheaper generics, but shares rose 1.5 percent on enthusiasm for newly announced cancer-drug partnerships with rival U.S. companies.
Feb 5- Merck& Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations. The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter.
Jan 28- Amgen Inc on Tuesday reported a quarterly profit that beat Wall Street forecasts, as it gained full control of its blockbuster rheumatoid arthritis drug Enbrel and saw solid growth in sales of newer products.
Jan 28- Amgen Inc on Tuesday reported a forecast-beating quarterly profit, as the profit-sharing agreement on its blockbuster rheumatoid arthritis drug Enbrel became more favorable and on lower taxes.
Thursday's midday movers:
SAN FRANCISCO, Jan 14- Merck& Co's researchers need to regain their confidence after an eight-year drought in developing important new medicines sapped employee morale, the company's recently hired research chief told Reuters.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Three exchange-traded funds that don't track the traditional plain-vanilla indexes.
Some of Thursday's midday movers.
Dec 19- Amgen Inc said its closely watched experimental cholesterol drug succeeded in reducing the level of bad cholesterol in the blood, compared to a placebo, in a late-stage trial. The data was consistent with the results from a large mid-stage trial that showed the drug, evolocumab, lowered LDL cholesterol by 52 percent after one year of treatment.
The breach came to light last month when the FDA sent letters to users of an online system at the Center for Biologics Evaluation and Research. The letters said the breach was detected by the FDA on Oct. 15 and that it resulted in the theft of usernames, phone numbers, email addresses and passwords.
*Bid at 27 percent premium to Algeta share price at Monday's close. *Algeta shares rise above Bayer offer price in early trade. OSLO/ LONDON, Nov 26- Bayer has offered to pay $2.4 billion for Norway's Algeta, its partner for a new prostate cancer treatment, at a 27 percent premium to the stock's last close, Algeta said on Tuesday.